Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-400: Lenvatinib vs Ramucirumab as Second-Line Therapy After Immunotherapy in Advanced HCC with High AFP
jRCT1031210092Phase 3Completed
- Sponsor
- Japan Oncology Network in Hepatobiliary and Pancreas
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in hepatocellular carcinoma (HCC) comparing Lenvatinib arm with Ramucirumab arm (2 arms). Primary endpoint: overall survival. Started Aug 2021; status: completed.
02
Drugs
lenvatinibramucirumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT1031210092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031210092.